Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)

Rothschedl E
Record ID 32018000344
Authors' results and conclusions: The ARAMIS trial showed that darolutamide provides a prolongation of metastasis-free survival (MFS) in patients with nonmetastatic CRPC and was associated with better outcomes regarding disease progression than in patients in the placebo group. However, the presented data are from the primary and interim analyses; final results of all endpoints are lacking. Hence, the actual clinical benefit of darolutamide is not yet proven. In this regard, more data concerning efficacy, safety and long-term results is required, as well as a direct comparison with other androgen receptor (AR) antagonists to determine the optimal treatment for affected patients. Darolutamide is currently not approved, but may provide an additional treatment option for patients with nonmetastatic CRPC.
Project Status: Completed
Year Published: 2019
URL for additional information: http://eprints.aihta.at/1199/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Therapeutics
  • Prostatic Neoplasms, Castration-Resistant
  • Pharmacology
  • Androgen Receptor Antagonists
  • Male
  • Quality of Life
  • Darolutamide
  • androgen-receptor antagonist
  • prostate cancer
  • castration-resistant
  • nonmetastatic
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.